Hemofiltration System for Acute Renal Failure

A new system provides continuous hemodialysis and other plasma therapies in critical care settings and is primarily designed for patients suffering from acute renal failure (ARF). The system has been cleared by the US Food and Drug Administration (FDA).

Traditionally, intermittent hemodialysis has been used to treat ARF patients, but increasingly, continuous therapies are being utilized that provide therapy for 24 hours a day for up to 30 days or more. The new system can be tailored to meet individual patient needs because of the capacity to handle a wide range of fluid volumes, from low to high. Increased fluid capacity means there may be a less-frequent need to exchange solutions bags during therapy, which reduces the workload of nurses and improves patient safety. The system can also deliver therapeutic plasma exchange (TPE), used to treat a variety of autoimmune and other serious disorders.

This Accura Hemofiltration System is the product of Baxter Healthcare Corp. (Deerfield, IL, USA). "The Accura system significantly enhances our comprehensive portfolio of products and services for acute renal failure patients and is also aligned with Baxter's core strength, which is providing critical therapies for people with life-threatening conditions,” said Richard G. Ganz, president of Baxter's renal business in North America.




Related Links:
Baxter